Oncology Medical News about Carcinoma, Non-Small-Cell Lung

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Phase I study of TLR9 agonist PF-3512676 in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer
Cancer Science, 10/23/09

Yamada K et al. – This phase I, open–label study investigated the Toll–like receptor 9 agonist, PF–3512676, in combination with carboplatin and paclitaxel in Japanese patients with advanced, non–small–cell lung cancer (NSCLC). PF–3512676 as monotherapy and in combination with chemotherapy had an acceptable safety profile in Japanese patients with treatment–naive NSCLC.

<< Previous
Improving sleep quality for cancer patients: benefits of a...

Next >>
Grading of gastric foveolar-type dysplasia in Barrett's esophagus

Treatment after the Failure of Gefitinib in Patients with Advanced or Recurrent Non-small Cell Lung Cancer
Anticancer Research, 11/13/09 Relevance Score: 80%

Phase II Study of Preoperative Gefitinib in Clinical Stage I Non-Small-Cell Lung Cancer
Journal of Clinical Oncology, 11/09/09 Relevance Score: 80%

Elevated serum levels of TPS and CYFRA 21-1 predict poor prognosis in advanced non-small-cell lung cancer patients treated with gefitinib
Medical Oncology, 11/05/09 Relevance Score: 80%

hsa-miR-125a-5p Enhances Invasion in Non-small Cell Lung Carcinoma Cell Lines by Upregulating Rock-1
Chinese Journal of Lung Cancer, 10/20/09 Relevance Score: 80%

An Embryonic Stem Cell–Like Signature Identifies Poorly Differentiated Lung Adenocarcinoma but not Squamous Cell Carcinoma
Clinical Cancer Research, 10/12/09 Relevance Score: 80%